Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | SRMS | Q9H3Y6 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355398 | 1.00 | SRC (1.00) | SRCABL1EGFRKDRRIPK2 | |
| Hydrochloric Acid SCHEMBL3784318 | 0.99 | SRC (0.97) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL14617301 | 0.93 | SRC (0.89) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL409444 | 0.89 | SRC (0.82) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL29432587 | 0.88 | SRC (1.00) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL407934 | 0.88 | SRC (1.00) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL15114667 | 0.87 | SRC (0.77) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL10098380 | 0.87 | SRC (0.77) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL13019680 | 0.87 | SRC (0.77) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL3610160 | 0.86 | SRC (0.95) | SRCABL1EGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20250302977-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2025-10-02 | — | — | US | claimed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | claimed |
| US-20250263654-A1 | PRIMORDIAL GERM CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-21 | — | — | US | claimed |
| WO-2025099152-A1 | ANTIBODIES AND MOLECULAR CONJUGATES THEREOF TARGETING UPAR | RIGSHOSPITALET (DK) | 2025-05-15 | — | — | WO | claimed |
| EP-4363447-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | Rigshospitalet (DK) | 2024-05-08 | — | — | EP | claimed |
| CN-117751140-A | Antibody-drug conjugates comprising humanized antibodies targeting urokinase-type plasminogen activator receptor-related protein (uPARAP) | 丹麦国家医院 | 2024-03-22 | — | — | CN | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| WO-2023275112-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2023-01-05 | — | — | WO | claimed |
| WO-2020058072-A1 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2020-03-26 | — | — | WO | claimed |
| US-9730926-B2 | Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-08-15 | — | — | US | claimed |
| US-20170202932-A1 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2017-07-20 | — | — | US | claimed |
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-06 | — | — | US | claimed |
| US-20150190366-A1 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2015-07-09 | — | — | US | claimed |
| EP-1482983-A4 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2006-07-12 | — | — | EP | claimed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| WO-2003065971-A9 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2003-11-20 | — | — | WO | claimed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SRC, MET, EGFR | SRC 1/4885ABL1 13/4885EGFR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.